Product Information
TROKENDI XR 100 MG CAPSULE is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $34.4376 per EA under NDC 17772010330. Its NADAC has been published 462 times since Nov 29, 2017.
FDA first approved this application on Aug 16, 2013. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the topiramate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
100 mg/1
Manufacturer
Supernus Pharmaceuticals Inc.NDC
17772010330
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
7/1/2026
Active Ingredients
TOPIRAMATEApproval Type
New Drug (NDA)
FDA Application
NDA201635FDA Approved
8/16/2013
TE Code
AB1
On Market Since
8/16/2013
Pharmacological Classes
Price Statistics
The NADAC for TROKENDI XR 100 MG CAPSULE has been published 462 times since Nov 29, 2017, and over the history we have for it it has risen 69.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $34.4376 per EA |
|---|---|
| All-time high | $34.4376 (Sep 30, 2026) |
| All-time low | $20.3081 (Nov 29, 2017) |
| 52-week high | $34.4376 |
| 52-week low | $31.7161 |
| Median price | $28.7769 |
| Average price | $27.6722 |
| Largest weekly change | +8.0% (Jan 9, 2019) |
| Weeks tracked | 462 |
| Tracking since | Nov 29, 2017 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 84% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Supernus Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TROKENDI XR 100 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TROKENDI XR 100 MG CAPSULE, manufactured by Supernus Pharmaceuticals Inc., is $34.4376 per EA (NDC 17772010330), effective Sep 30, 2026.
How has the price of TROKENDI XR 100 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TROKENDI XR 100 MG CAPSULE has risen 69.6%. It has been tracked across 462 weekly CMS publications since Nov 29, 2017.
What are the highest and lowest recorded NADAC prices for TROKENDI XR 100 MG CAPSULE?
Since Nov 29, 2017, the NADAC for TROKENDI XR 100 MG CAPSULE has ranged from a low of $20.3081 (Nov 29, 2017) to a high of $34.4376 (Sep 30, 2026), with a median of $28.7769 per EA.
Are there cheaper alternatives to TROKENDI XR 100 MG CAPSULE?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 100 MG SPRINK CAP, is $5.4921 per EA — about 84% below TROKENDI XR 100 MG CAPSULE.
Who manufactures TROKENDI XR 100 MG CAPSULE?
TROKENDI XR 100 MG CAPSULE (NDC 17772010330) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.